Does the media favor BHC or PTCT?

In the previous week, Bausch Health Cos had 8 more articles in the media than PTC Therapeutics. MarketBeat recorded 29 mentions for Bausch Health Cos and 21 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.93 beat Bausch Health Cos' score of 0.33 indicating that PTC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 6 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral PTC Therapeutics 13 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer BHC or XENE?

In the previous week, Bausch Health Cos had 11 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 29 mentions for Bausch Health Cos and 18 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.33 beat Bausch Health Cos' score of 0.33 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 6 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Xenon Pharmaceuticals 13 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BLTE or BHC?

In the previous week, Bausch Health Cos had 26 more articles in the media than Belite Bio. MarketBeat recorded 29 mentions for Bausch Health Cos and 3 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.22 beat Bausch Health Cos' score of 0.33 indicating that Belite Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch Health Cos 6 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CGON or BHC?

In the previous week, Bausch Health Cos had 16 more articles in the media than CG Oncology. MarketBeat recorded 29 mentions for Bausch Health Cos and 13 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.93 beat Bausch Health Cos' score of 0.33 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 7 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch Health Cos 6 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Bausch Health Cos (BHC) Competitors

$6.90 +0.01 (+0.09%)

Closing price 07/31/2026 03:59 PM Eastern

Extended Trading

$6.92 +0.02 (+0.33%)

As of 07/31/2026 08:00 PM Eastern

Compare

BHC vs. PTCT, XENE, CNTA, BLTE, and CGON

Should you buy Bausch Health Cos stock or one of its competitors? MarketBeat compares Bausch Health Cos with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bausch Health Cos include PTC Therapeutics (PTCT), Xenon Pharmaceuticals (XENE), Centessa Pharmaceuticals (CNTA), Belite Bio (BLTE), and CG Oncology (CGON).

How does Bausch Health Cos compare to PTC Therapeutics?

Bausch Health Cos (NYSE:BHC) and PTC Therapeutics (NASDAQ:PTCT) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

78.7% of Bausch Health Cos shares are held by institutional investors. 20.7% of Bausch Health Cos shares are held by company insiders. Comparatively, 5.3% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Bausch Health Cos presently has a consensus price target of $8.00, indicating a potential upside of 16.01%. PTC Therapeutics has a consensus price target of $95.75, indicating a potential upside of 40.79%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe PTC Therapeutics is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.79

PTC Therapeutics has a net margin of -3.80% compared to Bausch Health Cos' net margin of -10.12%. PTC Therapeutics' return on equity of -362.45% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-10.12%	-561.95%	6.31%
PTC Therapeutics	-3.80%	-362.45%	-1.32%

PTC Therapeutics has lower revenue, but higher earnings than Bausch Health Cos. PTC Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.85B	0.24	$157M	-$2.96	N/A
PTC Therapeutics	$1.73B	3.26	$682.64M	-$0.58	N/A

Bausch Health Cos has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

In the previous week, Bausch Health Cos had 8 more articles in the media than PTC Therapeutics. MarketBeat recorded 29 mentions for Bausch Health Cos and 21 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.93 beat Bausch Health Cos' score of 0.33 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	6 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
PTC Therapeutics	13 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

PTC Therapeutics beats Bausch Health Cos on 11 of the 17 factors compared between the two stocks.

How does Bausch Health Cos compare to Xenon Pharmaceuticals?

Bausch Health Cos (NYSE:BHC) and Xenon Pharmaceuticals (NASDAQ:XENE) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

In the previous week, Bausch Health Cos had 11 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 29 mentions for Bausch Health Cos and 18 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.33 beat Bausch Health Cos' score of 0.33 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	6 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenon Pharmaceuticals	13 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.7% of Bausch Health Cos shares are owned by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 20.7% of Bausch Health Cos shares are owned by company insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bausch Health Cos has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

Bausch Health Cos currently has a consensus target price of $8.00, indicating a potential upside of 16.01%. Xenon Pharmaceuticals has a consensus target price of $77.20, indicating a potential upside of 23.18%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Bausch Health Cos has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.85B	0.24	$157M	-$2.96	N/A
Xenon Pharmaceuticals	$7.50M	807.77	-$345.91M	-$4.70	N/A

Xenon Pharmaceuticals has a net margin of 0.00% compared to Bausch Health Cos' net margin of -10.12%. Xenon Pharmaceuticals' return on equity of -49.23% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-10.12%	-561.95%	6.31%
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

Summary

Xenon Pharmaceuticals beats Bausch Health Cos on 10 of the 17 factors compared between the two stocks.

How does Bausch Health Cos compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Bausch Health Cos (NYSE:BHC) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

Bausch Health Cos has higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A
Bausch Health Cos	$10.85B	0.24	$157M	-$2.96	N/A

Centessa Pharmaceuticals presently has a consensus price target of $41.33, indicating a potential upside of 2.06%. Bausch Health Cos has a consensus price target of $8.00, indicating a potential upside of 16.01%. Given Bausch Health Cos' higher probable upside, analysts plainly believe Bausch Health Cos is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Bausch Health Cos	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

In the previous week, Bausch Health Cos had 29 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 29 mentions for Bausch Health Cos and 0 mentions for Centessa Pharmaceuticals. Bausch Health Cos' average media sentiment score of 0.33 beat Centessa Pharmaceuticals' score of 0.00 indicating that Bausch Health Cos is being referred to more favorably in the news media.

Company	Overall Sentiment
Centessa Pharmaceuticals	Neutral
Bausch Health Cos	Neutral

Centessa Pharmaceuticals has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

Centessa Pharmaceuticals has a net margin of 0.00% compared to Bausch Health Cos' net margin of -10.12%. Centessa Pharmaceuticals' return on equity of -60.37% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Bausch Health Cos	-10.12%	-561.95%	6.31%

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Bausch Health Cos beats Centessa Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Bausch Health Cos compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Bausch Health Cos (NYSE:BHC) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 20.7% of Bausch Health Cos shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Belite Bio has a net margin of 0.00% compared to Bausch Health Cos' net margin of -10.12%. Belite Bio's return on equity of -13.14% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
Bausch Health Cos	-10.12%	-561.95%	6.31%

Belite Bio has a beta of -1.22, meaning that its stock price is 222% less volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market.

Belite Bio presently has a consensus target price of $203.00, suggesting a potential upside of 27.99%. Bausch Health Cos has a consensus target price of $8.00, suggesting a potential upside of 16.01%. Given Belite Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Belite Bio is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Bausch Health Cos	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Bausch Health Cos has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A
Bausch Health Cos	$10.85B	0.24	$157M	-$2.96	N/A

In the previous week, Bausch Health Cos had 26 more articles in the media than Belite Bio. MarketBeat recorded 29 mentions for Bausch Health Cos and 3 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.22 beat Bausch Health Cos' score of 0.33 indicating that Belite Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch Health Cos	6 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Belite Bio and Bausch Health Cos tied by winning 8 of the 16 factors compared between the two stocks.

How does Bausch Health Cos compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Bausch Health Cos (NYSE:BHC) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

CG Oncology has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market.

In the previous week, Bausch Health Cos had 16 more articles in the media than CG Oncology. MarketBeat recorded 29 mentions for Bausch Health Cos and 13 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.93 beat Bausch Health Cos' score of 0.33 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	7 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch Health Cos	6 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bausch Health Cos has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$5.07M	1,238.24	-$160.99M	-$2.33	N/A
Bausch Health Cos	$10.85B	0.24	$157M	-$2.96	N/A

CG Oncology has a net margin of 0.00% compared to Bausch Health Cos' net margin of -10.12%. CG Oncology's return on equity of -23.33% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
Bausch Health Cos	-10.12%	-561.95%	6.31%

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 4.8% of CG Oncology shares are held by company insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

CG Oncology currently has a consensus target price of $81.73, suggesting a potential upside of 14.80%. Bausch Health Cos has a consensus target price of $8.00, suggesting a potential upside of 16.01%. Given Bausch Health Cos' higher possible upside, analysts plainly believe Bausch Health Cos is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Bausch Health Cos	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Summary

Bausch Health Cos beats CG Oncology on 9 of the 16 factors compared between the two stocks.

Get Bausch Health Cos News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BHC vs. The Competition

Export

Metric	Bausch Health Cos	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$2.58B	$11.71B	$6.85B	$23.66B
Dividend Yield	N/A	2.72%	2.59%	4.22%
P/E Ratio	-2.33	799.05	282.30	31.00
Price / Sales	0.24	748.51	563.12	81.86
Price / Cash	0.95	14.82	28.60	18.73
Price / Book	6.76	10.28	10.96	4.76
Net Income	$157M	$2.82B	$3.49B	$1.07B
7 Day Performance	53.76%	-0.16%	-0.64%	-0.34%
1 Month Performance	40.02%	-4.00%	-5.23%	-0.53%
1 Year Performance	20.77%	156.08%	61.97%	19.19%

Bausch Health Cos Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BHC Bausch Health Cos	2.1428 of 5 stars	$6.90 +0.1%	$8.00 +16.0%	+20.8%	$2.58B	$10.85B	N/A	20,300	Earnings Report Analyst Upgrade Gap Down High Trading Volume
PTCT PTC Therapeutics	4.4326 of 5 stars	$75.80 -1.3%	$92.29 +21.7%	+30.5%	$6.37B	$1.73B	N/A	1,410	Trending News Earnings Report Analyst Forecast
XENE Xenon Pharmaceuticals	3.1252 of 5 stars	$65.78 +0.6%	$77.20 +17.4%	+105.5%	$6.32B	$7.50M	N/A	210	Positive News Upcoming Earnings Analyst Upgrade
CNTA Centessa Pharmaceuticals	N/A	$40.50 flat	$41.33 +2.1%	N/A	$6.27B	N/A	N/A	200
BLTE Belite Bio	3.4607 of 5 stars	$158.43 +3.3%	$203.00 +28.1%	+141.3%	$6.15B	N/A	N/A	10	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BHC) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bausch Health Cos (BHC) Competitors

BHC vs. PTCT, XENE, CNTA, BLTE, and CGON

How does Bausch Health Cos compare to PTC Therapeutics?

Summary

How does Bausch Health Cos compare to Xenon Pharmaceuticals?

Summary

How does Bausch Health Cos compare to Centessa Pharmaceuticals?

Summary

How does Bausch Health Cos compare to Belite Bio?

Summary

How does Bausch Health Cos compare to CG Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHC vs. The Competition

Bausch Health Cos Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bausch Health Cos (BHC) Competitors

BHC vs. PTCT, XENE, CNTA, BLTE, and CGON

How does Bausch Health Cos compare to PTC Therapeutics?

Do insiders & institutionals have more ownership in BHC or PTCT?

Do analysts prefer BHC or PTCT?

Is BHC or PTCT more profitable?

Which has higher earnings and valuation, BHC or PTCT?

Which has more risk & volatility, BHC or PTCT?

Does the media favor BHC or PTCT?

Summary

How does Bausch Health Cos compare to Xenon Pharmaceuticals?

Does the media prefer BHC or XENE?

Do institutionals & insiders have more ownership in BHC or XENE?

Which has more volatility & risk, BHC or XENE?

Do analysts recommend BHC or XENE?

Which has better valuation & earnings, BHC or XENE?

Is BHC or XENE more profitable?

Summary

How does Bausch Health Cos compare to Centessa Pharmaceuticals?

Which has better earnings & valuation, CNTA or BHC?

Do analysts rate CNTA or BHC?

Does the media prefer CNTA or BHC?

Which has more volatility & risk, CNTA or BHC?

Is CNTA or BHC more profitable?

Do insiders and institutionals believe in CNTA or BHC?

Summary

How does Bausch Health Cos compare to Belite Bio?

Do institutionals and insiders hold more shares of BLTE or BHC?

Is BLTE or BHC more profitable?

Which has more risk & volatility, BLTE or BHC?

Do analysts recommend BLTE or BHC?

Which has higher valuation and earnings, BLTE or BHC?

Does the media favor BLTE or BHC?

Summary

How does Bausch Health Cos compare to CG Oncology?

Which has more volatility and risk, CGON or BHC?

Does the media prefer CGON or BHC?

Which has stronger earnings and valuation, CGON or BHC?

Is CGON or BHC more profitable?

Do institutionals & insiders believe in CGON or BHC?

Do analysts rate CGON or BHC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHC vs. The Competition

Bausch Health Cos Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools